東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Innovations for next-generation anti...

Damelin, Marc.

FindBook

Google Book

Amazon

博客來

Innovations for next-generation antibody-drug conjugates

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Innovations for next-generation antibody-drug conjugates/ edited by Marc Damelin.
其他作者:	Damelin, Marc.
出版者:	Cham :Springer International Publishing : : 2018.,
面頁冊數:	viii, 357 p. :ill., digital ;24 cm.
內容註:	Chapter 1 Introduction: Motivations for Next-Generation ADCs -- Chapter 2 Combining ADCs with Immuno-oncology Agents -- Chapter 3 Improving the Safety Profile of ADCs -- Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development -- Chapter 5 Regulatory Considerations and Companion Diagnostics -- Chapter 6 ADC Process Development and Manufacturing -- Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development -- Chapter 8 Next generation payloads for ADCs -- Chapter 9 Delivering more payload: High DAR ADCs -- Chapter 10 Site-Specific Antibody Drug Conjugates -- Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates -- Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates -- Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment -- Chapter 14 Next Horizons: ADCs Beyond Oncology.
Contained By:	Springer eBooks
標題:	Medicine. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-78154-9
ISBN:	9783319781549

Innovations for next-generation antibody-drug conjugates
Innovations for next-generation antibody-drug conjugates[electronic resource] /edited by Marc Damelin. - Cham :Springer International Publishing :2018. - viii, 357 p. :ill., digital ;24 cm. - Cancer drug discovery and development,2196-9906. - Cancer drug discovery and development..

Chapter 1 Introduction: Motivations for Next-Generation ADCs -- Chapter 2 Combining ADCs with Immuno-oncology Agents -- Chapter 3 Improving the Safety Profile of ADCs -- Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development -- Chapter 5 Regulatory Considerations and Companion Diagnostics -- Chapter 6 ADC Process Development and Manufacturing -- Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development -- Chapter 8 Next generation payloads for ADCs -- Chapter 9 Delivering more payload: High DAR ADCs -- Chapter 10 Site-Specific Antibody Drug Conjugates -- Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates -- Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates -- Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment -- Chapter 14 Next Horizons: ADCs Beyond Oncology.

Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field's history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.

ISBN: 9783319781549

Standard No.: 10.1007/978-3-319-78154-9doiSubjects--Topical Terms:

641104
Medicine.

LC Class. No.: RC261

Dewey Class. No.: 615.37

Innovations for next-generation antibody-drug conjugates
LDR:03149nmm a2200325 a 4500 001 2146301
003 DE-He213
005 20181204143629.0
006 m d
007 cr nn 008maaau
008 190227s2018 gw s 0 eng d
020 $a 9783319781549 $q (electronic bk.)
020 $a 9783319781532 $q (paper)
024 7 $a 10.1007/978-3-319-78154-9 $2 doi
035 $a 978-3-319-78154-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RC261
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 615.37 $2 23
090 $a RC261 $b .I58 2018
245 0 0 $a Innovations for next-generation antibody-drug conjugates $h [electronic resource] / $c edited by Marc Damelin.
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana Press, $c 2018.
300 $a viii, 357 p. : $b ill., digital ; $c 24 cm.
490 1 $a Cancer drug discovery and development, $x 2196-9906
505 0 $a Chapter 1 Introduction: Motivations for Next-Generation ADCs -- Chapter 2 Combining ADCs with Immuno-oncology Agents -- Chapter 3 Improving the Safety Profile of ADCs -- Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development -- Chapter 5 Regulatory Considerations and Companion Diagnostics -- Chapter 6 ADC Process Development and Manufacturing -- Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development -- Chapter 8 Next generation payloads for ADCs -- Chapter 9 Delivering more payload: High DAR ADCs -- Chapter 10 Site-Specific Antibody Drug Conjugates -- Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates -- Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates -- Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment -- Chapter 14 Next Horizons: ADCs Beyond Oncology.
520 $a Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field's history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
650 0 $a Medicine. $3 641104
650 0 $a Cancer $x Research. $3 696466
650 0 $a Molecular biology. $3 517296
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Cancer Research. $3 891172
650 2 4 $a Molecular Medicine. $3 890952
700 1 $a Damelin, Marc. $3 3332740
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Cancer drug discovery and development. $3 1565408
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-78154-9
950 $a Medicine (Springer-11650)